BioNTech will be able to adapt its coronavirus vaccine relatively quickly to treat the new mutant strain Omicron, the company’s CEO Ugur Sahin said on Friday, speaking at Reuters Next.
Sahin also added that the existing vaccines will logically continue to provide protection against the serious disease, despite the mutations.
“This mutation could infect vaccinated people. We expect that those who have been vaccinated will continue to be protected from the serious disease,” Sahin said.
The CEO of BioNTech also stressed that mutations in the new coronavirus make annual vaccination more likely to be necessary, as is the case with seasonal flu.
It is noteworthy, however, that not much information is yet known about the new mutant strain Omicron, which was first identified in South Africa last month and has already been identified in more than 20 countries around the world, while some countries Europe was already hit by a new wave of cases due to the Delta variant.
.
Source From: Capital
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.